4:16 PM ET
10-Q
Financial Results
Attovia Therapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Widens
Attovia Therapeutics is an emerging growth company focused on developing product candidates ATTO-1310, ATTO-2306, and ATTO-1091 for inflammatory and pruritic diseases. As of October 31, 2026, the company had 45,712,536 shares of common stock outstanding and continues to incur significant operating losses with no product revenue generated to date.
- Key figure
- Net loss $22.3M